Posted on July 23, 2018 by staff

NHS patients to benefit from new health tech collaboration


Health tech accelerator HS. has partnered with GP-on-demand service GPDQ in a move which will drive innovation into primary care.

GPDQ has delivered services to 5,000 patients in their own homes and workplaces to date, and works with more than 60 NHS GPs at the forefront of patient care.

It believes the collaboration will bridge the chasm that has traditionally existed between entrepreneurs and UK GP services.

“GPDQ’s mission to build sustainable healthcare systems through community-based primary care involves putting NHS GPs and patients at the heart of broader health tech innovation,” said GPDQ CEO Paul Roberts.

“GPs have a big role to play in supporting patient-facing trials, and we’re proud to offer a key link that has been difficult for innovators to access until now.

“Our partnership with HS. enables us to work with other innovators to put new technology into the hands of our NHS GPs and develop solutions that bring together the best of both worlds – technology with a human touch.

“Together, we provide a crucial link to deliver patient-facing, real-world test-beds for innovations.”

HS. launched in April yet already has an established ecosystem to build, scale and invest in health tech start-ups.

Its founding partner Dr James Somauroo recently told BusinessCloud that the FinTech sector is reaching a peak and that health tech is set to take over as the darling of the UK investor community.

He said of the new partnership: “We have now built the fastest and most impactful route to market for anyone with an idea or solution in primary care.

“Of the 100 cutting-edge health tech start-ups HS. will be supporting over the next 12 months, we want half of them to be focused on providing benefit to primary care to gain from this incredible route to market.”

One of the innovators taking part in the partnership is Feebris, whose AI and machine learning platform can ease the burden on the primary care system by accurately predicting and preventing disease in children and the elderly.

Its founder Elina Naydenova said: “As one of the very first start-ups to be accepted onto the HS. accelerator programme, we have witnessed the incredible value of working with industry experts, as well as clinicians who can use Feebris to make a difference in their care for patients.

“Through HS. and GPDQ, amazing access to networks that would otherwise have taken years to gain, if ever at all, have already proven to be such a benefit, enabling us to keep evolving and gain vital traction, helping us to make impact where it matters most: on the frontline of the NHS.”